Apoptosis in human cancer cells

被引:80
作者
Yu, J
Zhang, L
机构
[1] Univ Pittsburgh, Inst Canc, Hillman Canc Ctr, Dept Pathol, Pittsburgh, PA 15213 USA
[2] Univ Pittsburgh, Inst Canc, Dept Pharmacol, Pittsburgh, PA 15213 USA
关键词
apoptosis; cancer Bcl-2 family proteins; mitochondria; anticancer therapy;
D O I
10.1097/00001622-200401000-00005
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose of review: Apoptosis, or programed cell death, is a vital physiologic process to eliminate damaged or unwanted cells. Defects in apoptosis promote tumor formation and make cancer cells resistant to therapy. This review provides an overview of recent advances in the understanding of apoptosis in human cancer cells. Recent findings: Recent studies revealed that the apoptotic machinery in humans consists of a molecular network of a large number of proteins. These proteins regulate a cascade of events in signaling, commitment and execution stages of apoptosis through multiple parallel pathways. Delineation of the basic mechanisms of apoptosis has shed light on how apoptosis is deregulated in human cancer cells. Therapeutic strategies based on apoptosis have also been designed to selectively target tumor cells. Summary: Understanding the basic mechanisms of apoptosis and determining how cancer cells evade apoptosis will afford discoveries of new molecular targets and better cancer therapies.
引用
收藏
页码:19 / 24
页数:6
相关论文
共 73 条
  • [1] Apo2L/TRAIL: apoptosis signaling, biology, and potential for cancer therapy
    Almasan, A
    Ashkenazi, A
    [J]. CYTOKINE & GROWTH FACTOR REVIEWS, 2003, 14 (3-4) : 337 - 348
  • [2] Amundson SA, 2000, CANCER RES, V60, P6101
  • [3] Apoptotic molecular machinery: Vastly increased complexity in vertebrates revealed by genome comparisons
    Aravind, L
    Dixit, VM
    Koonin, EV
    [J]. SCIENCE, 2001, 291 (5507) : 1279 - +
  • [4] p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis
    Bergamaschi, D
    Gasco, M
    Hiller, L
    Sullivan, A
    Syed, N
    Trigiante, G
    Yulug, I
    Merlano, M
    Numico, G
    Comino, A
    Attard, M
    Reelfs, O
    Gusterson, B
    Bell, AK
    Heath, V
    Tavassoli, M
    Farrell, PJ
    Smith, P
    Lu, X
    Crook, T
    [J]. CANCER CELL, 2003, 3 (04) : 387 - 402
  • [5] Proapoptotic Bcl-2 relative bim required for certain apoptotic responses, leukocyte homeostasis, and to preclude autoimmunity
    Bouillet, P
    Metcalf, D
    Huang, DCS
    Tarlinton, DM
    Kay, TWH
    Köntgen, F
    Adams, JM
    Strasser, A
    [J]. SCIENCE, 1999, 286 (5445) : 1735 - 1738
  • [6] Nitric oxide:: NO apoptosis or turning it ON?
    Brüne, B
    [J]. CELL DEATH AND DIFFERENTIATION, 2003, 10 (08) : 864 - 869
  • [7] Disruption of p53 in human cancer cells alters the responses to therapeutic agents
    Bunz, F
    Hwang, PM
    Torrance, C
    Waldman, T
    Zhang, YG
    Dillehay, L
    Williams, J
    Lengauer, C
    Kinzler, KW
    Vogelstein, B
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1999, 104 (03) : 263 - 269
  • [8] Human cell knockouts
    Bunz, F
    [J]. CURRENT OPINION IN ONCOLOGY, 2002, 14 (01) : 73 - 78
  • [9] VDAC2 inhibits BAK activation and mitochondrial apoptosis
    Cheng, EHY
    Sheiko, TV
    Fisher, JK
    Craigen, WJ
    Korsmeyer, SJ
    [J]. SCIENCE, 2003, 301 (5632) : 513 - 517
  • [10] BCL-2, BCL-XL sequester BH3 domain-only molecules preventing BAX- and BAK-mediated mitochondrial apoptosis
    Cheng, EHYA
    Wei, MC
    Weiler, S
    Flavell, RA
    Mak, TW
    Lindsten, T
    Korsmeyer, SJ
    [J]. MOLECULAR CELL, 2001, 8 (03) : 705 - 711